The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- d -aspartate receptor activity
Open accessAbstract
The molecular and neuronal substrates conferring on clozapine its unique and superior efficacy in the treatment of schizophrenia remain elusive. The interaction of clozapine with many G protein-coupled receptors is well documented but less is known about its biologically active metabolite, N -desmethylclozapine. Recent clinical and preclinical evidences of the antipsychotic activity of the muscarinic agonist xanomeline prompted us to investigate the effects of N -desmethylclozapine on cloned human M1-M5 muscarinic receptors. N -desmethylclozapine preferentially bound to M1 muscarinic receptors with an IC 50 of 55 nM and was a more potent partial agonist (EC 50 , 115 nM and 50% of acetylcholine response) at this receptor than clozapine. Furthermore, pharmacological and site-directed mutagenesis studies suggested that N -desmethylclozapine preferentially activated M1 receptors by interacting with a site that does not fully overlap with the acetylcholine orthosteric site. As hypofunction of N -methyl- d -aspartate (NMDA) receptor-driven neuronal ensembles has been implicated in psychotic disorders, the neuronal activity of N -desmethylclozapine was electrophysiologically investigated in hippocampal rat brain slices. N -desmethylclozapine was shown to dose-dependently potentiate NMDA receptor currents in CA1 pyramidal cells by 53% at 100 nM, an effect largely mediated by activation of muscarinic receptors. Altogether, our observations provide direct evidence that the brain penetrant metabolite N -desmethylclozapine is a potent, allosteric agonist at human M1 receptors and is able to potentiate hippocampal NMDA receptor currents through M1 receptor activation. These observations raise the possibility that N -desmethylclozapine contributes to clozapine's clinical activity in schizophrenics through modulation of both muscarinic and glutamatergic neurotransmission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H. E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., et al. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550160091022 · Cited by 692
Clozapine: A Novel Antipsychotic Agent
Oates, J. A., Wood, A. J. J., Baldessarini, R. J., & Frankenburg, F. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103143241107 · Cited by 687
Allosteric binding sites on cell-surface receptors: novel targets for drug discovery
Christopoulos, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd746 · Cited by 664
Glutamatergic mechanisms in schizophrenia
Tsai, G., & Coyle, J. T. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.082701.160735 · Cited by 577
Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice
Anagnostaras, S. G., Murphy, G. G., Hamilton, S. E., Mitchell, S. L., Rahnama, N. P., Nathanson, N. M., & Silva, A. J. (2003) · Nature Neuroscience · doi:10.1038/nn992 · Cited by 544
Seeman, P. (1992) · PubMed · Cited by 439
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.183 · Cited by 436
Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.255 · Cited by 407
Miyakawa, T., Yamada, M., Duttaroy, A., & Wess, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-14-05239.2001 · Cited by 370
Marino, M. J., Rouse, S. T., Levey, A. I., Potter, L. T., & Conn, P. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11465 · Cited by 275
Self-citationBolden, C., Cusack, B., & Richelson, E. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11335-9 · Cited by 272
Gerber, D. J., Sotnikova, T. D., Gainetdinov, R. R., Huang, S. Y., Caron, M. G., & Tonegawa, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261583798 · Cited by 264
Tissue Concentrations of Clozapine and its Metabolites in the Rat
Baldessarini, R. J., Centorrino, F., Flood, J. G., Volpicelli, S. A., Huston-Lyons, D., & Cohen, B. M. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.50 · Cited by 233
Jakubík, J., Bačáková, L., El-Fakahany, E. E., & Tuček, S. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.1.172 · Cited by 228
Discovery of an Ectopic Activation Site on the M1Muscarinic Receptor
Spalding, T. A., Trotter, C., Skjærbæk, N., Messier, T. L., Currier, E. A., Burstein, E. S., Li, D., Hacksell, U., & Brann, M. R. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12088-3 · Cited by 193
Clozapine is a potent and selective muscarinic M4 receptor agonist
Zorn, S. H., Jones, S. B., Ward, K. M., & Liston, D. R. (1994) · European Journal of Pharmacology: Molecular Pharmacology · doi:10.1016/0922-4106(94)90047-7 · Cited by 191
Shannon, H. E., Rasmussen, K., Bymaster, F. P., Hart, J. C., Peters, S. C., Swedberg, M. D. B., Jeppesen, L., Sheardown, M. J., Sauerberg, P., & Fink-Jensen, A. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00138-3 · Cited by 165
Arvanov, V. L., Liang, X., Schwartz, J., Grossman, S., & Wang, R. Y. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37013-2 · Cited by 162
Centorrino, F., Baldessarini, R. J., Frankenburg, F. R., Kando, J. C., Volpicelli, S. A., & Flood, J. G. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.6.820 · Cited by 151
The Muscarinic Receptor Agonist Xanomeline Has an Antipsychotic-Like Profile in the Rat
Stanhope, K. J., Mirza, N. R., Bickerdike, M. J., Bright, J. L., Harrington, N. R., Hesselink, M. B., Kennett, G. A., Lightowler, S., Sheardown, M. J., Syed, R., et al. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29291-0 · Cited by 142
Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists
Kuoppamäki, M., Syvälahti, E. K. G., & Hietala, J. A. (1993) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(93)90126-t · Cited by 127
Lazareno, S., Gharagozloo, P., Kuonen, D. R., Popham, A., & Birdsall, N. J. M. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.3.573 · Cited by 121
Özdemir, V., KALOW, W., Okey, A. B., Lam, M. S. M., Albers, L. J., Reist, C., Fourie, J., Posner, P., Collins, E. J., & Roy, R. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200112000-00011 · Cited by 99
Muscarinic m4 receptor activation by some atypical antipsychotic drugs
Zeng, X. P., Le, F., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00956-9 · Cited by 93
Brandish, P. E., Hill, L. A., Zheng, W., & Scolnick, E. M. (2003) · Analytical Biochemistry · doi:10.1016/s0003-2697(02)00630-9 · Cited by 79
Self-citationOlianas, M. C., Maullu, C., & Onali, P. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00048-7 · Cited by 71
Distribution of clozapine and desmethylclozapine between blood and brain in rats
Weigmann, H., Härtter, S., Fischer, V., Dahmen, N., & Hiemke, C. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)00036-4 · Cited by 64
Ward, S. D. C., CURTIS, C. A. M., & Hulme, E. C. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12783-6 · Cited by 64
Delirium: a subcortical phenomenon?
Trzepacz, P. T., Sclabassi, R. J., & Thiel, D. H. V. (1989) · Journal of Neuropsychiatry · doi:10.1176/jnp.1.3.283 · Cited by 61
Olianas, M. C., Maullu, C., & Onali, P. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701357 · Cited by 56
Current issues in the psychopharmacology of schizophrenia
Breier, A. F., Tran, P., Herrera, J. M., Tollefson, G. D., & Bymaster, F. P. (2001) · Lippincott Williams & Wilkins eBooks · Cited by 38
C Young, P. D. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00203-0 · Cited by 26
Agbotounou, W. K., Umezawa, K., Jacquemin‐Sablon, A., & Pierre, J. (1994) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(94)90019-1 · Cited by 18
Cited by
Armbruster, B. N., Li, X., Pausch, M. H., Herlitze, S., & Roth, B. L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700293104 · Cited by 2,046
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development
Wess, J., Eglen, R. M., & Gautam, D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2379 · Cited by 637
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Metadata
- Authors
- Sur, C., Mallorga, P. J., Wittmann, M., Jacobson, M. A., Pascarella, D., Williams, J. B., Brandish, P. E., Pettibone, D. J., Scolnick, E. M., & Conn, P. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-10-31
- Volume
- 100
- Issue
- 23
- Pages
- 13674-13679
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2016278859
- Cited by
- 294
- References
- 36
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.